CLOBETASOL PROPIONATE

CLOBETASOL PROPIONATE was reported 10734 times

CLOBETASOL PROPIONATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TOPICAL STEROID WITHDRAWAL REACTION 30 0.0771
1 CUSHING'S SYNDROME 50 0.0719
2 ALOPECIA SCARRING 9 0.0492
3 HYPOTHALAMIC PITUITARY ADRENAL AXIS SUPPRESSION 17 0.0474
4 BRONCHIOLITIS OBLITERANS SYNDROME 8 0.0457
5 GREATER TROCHANTERIC PAIN SYNDROME 9 0.0439
6 BILIARY SEPSIS 14 0.0302
7 LICHEN SCLEROSUS 18 0.0263
8 BLOOD CORTISOL DECREASED 13 0.0203
9 SKIN ATROPHY 113 0.0196
10 ADRENAL SUPPRESSION 14 0.0166
11 HUMAN HERPESVIRUS 8 INFECTION 10 0.0164
12 BLOOD CORTICOTROPHIN DECREASED 8 0.0164
13 LENTIGO 8 0.0161
14 SKIN WEEPING 56 0.0157
15 NEOPLASM SKIN 22 0.0142
16 STEROID WITHDRAWAL SYNDROME 14 0.0137
17 SKIN CANDIDA 7 0.0134
18 CENTRAL SEROUS CHORIORETINOPATHY 9 0.0132
19 CUSHINGOID 42 0.0131
20 TERMINAL ILEITIS 8 0.0130
21 SKIN STRIAE 19 0.0128
22 SEBORRHOEIC KERATOSIS 18 0.0124
23 CENTRAL OBESITY 9 0.0122
24 ERYTHRODERMIC PSORIASIS 10 0.0121
25 BETA HAEMOLYTIC STREPTOCOCCAL INFECTION 13 0.0103
26 LICHEN PLANUS 23 0.0099
27 SKIN FISSURES 188 0.0096
28 NECROTISING FASCIITIS 33 0.0094
29 SECONDARY ADRENOCORTICAL INSUFFICIENCY 14 0.0093
30 XEROSIS 11 0.0089
31 SKIN BACTERIAL INFECTION 7 0.0087
32 STEROID DIABETES 13 0.0087
33 ACARODERMATITIS 9 0.0082
34 ACINETOBACTER INFECTION 9 0.0082
35 PRODUCT PHYSICAL CONSISTENCY ISSUE 45 0.0081
36 HYPERGLYCAEMIC HYPEROSMOLAR NONKETOTIC SYNDROME 9 0.0081
37 RADICULOPATHY 21 0.0080
38 SQUAMOUS CELL CARCINOMA OF SKIN 48 0.0079
39 SEBORRHOEIC DERMATITIS 13 0.0079
40 ENTHESOPATHY 12 0.0077
41 SKIN HAEMORRHAGE 113 0.0076
42 CHRONIC GRAFT VERSUS HOST DISEASE IN SKIN 7 0.0076
43 PEMPHIGOID 54 0.0071
44 EYE ALLERGY 11 0.0071
45 CHEMICAL BURN 8 0.0069
46 EYELID SKIN DRYNESS 8 0.0066
47 SKIN SWELLING 57 0.0066
48 REBOUND ATOPIC DERMATITIS 13 0.0065
49 INFUSION SITE DISCHARGE 11 0.0063
50 TENOSYNOVITIS 17 0.0062
51 SKIN HYPERTROPHY 17 0.0060
52 NEURODERMATITIS 22 0.0059
53 SKIN WOUND 10 0.0059
54 DERMATITIS ATOPIC 302 0.0057
55 DERMATITIS BULLOUS 41 0.0057
56 PUSTULE 13 0.0055
57 ESSENTIAL HYPERTENSION 10 0.0055
58 MACULE 15 0.0054
59 ECZEMA 282 0.0054
60 DECREASED INTEREST 31 0.0053
61 PAPULE 37 0.0052
62 ROSACEA 24 0.0051
63 CUTANEOUS LUPUS ERYTHEMATOSUS 10 0.0051
64 ONYCHOLYSIS 8 0.0051
65 SKIN HYPOPIGMENTATION 9 0.0051
66 OSTEOSCLEROSIS 8 0.0051
67 PUSTULAR PSORIASIS 17 0.0049
68 EYELID PAIN 10 0.0049
69 DERMATITIS PSORIASIFORM 10 0.0049
70 HYPERTRICHOSIS 9 0.0049
71 SKIN EXFOLIATION 404 0.0048
72 IMPETIGO 7 0.0047
73 URINARY TRACT DISORDER 21 0.0047
74 JOINT NOISE 9 0.0046
75 LACK OF INJECTION SITE ROTATION 8 0.0046
76 BRONCHIAL DISORDER 7 0.0045
77 INCORRECT DOSAGE ADMINISTERED 22 0.0045
78 LICHENOID KERATOSIS 10 0.0044
79 APPLICATION SITE INFLAMMATION 6 0.0043
80 PRODUCT CONTAINER ISSUE 37 0.0043
81 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 73 0.0043
82 PSORIASIS 561 0.0043
83 SKIN PLAQUE 35 0.0041
84 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 11 0.0041
85 STREPTOCOCCAL INFECTION 23 0.0041
86 LUMBAR SPINAL STENOSIS 12 0.0041
87 ANGIOPLASTY 6 0.0040
88 ALOPECIA AREATA 7 0.0040
89 VASODILATATION 10 0.0040
90 SCRATCH 41 0.0039
91 SKIN INDURATION 8 0.0039
92 EYELID MARGIN CRUSTING 11 0.0038
93 ONYCHOCLASIS 26 0.0038
94 SKIN EROSION 12 0.0037
95 MELANOCYTIC NAEVUS 16 0.0036
96 DANDRUFF 8 0.0036
97 ADRENOCORTICAL INSUFFICIENCY ACUTE 7 0.0036
98 PSORIATIC ARTHROPATHY 144 0.0035
99 BLOOD BLISTER 11 0.0035
100 CEREBRAL DISORDER 26 0.0035
101 DERMATITIS CONTACT 40 0.0035
102 SCAB 40 0.0035
103 ACTINIC KERATOSIS 9 0.0035
104 DERMATITIS EXFOLIATIVE GENERALISED 12 0.0034
105 APPLICATION SITE PAIN 76 0.0034
106 HYPERKERATOSIS 19 0.0034
107 REBOUND ECZEMA 7 0.0034
108 EXFOLIATIVE RASH 9 0.0034
109 DERMATITIS 71 0.0034
110 GLUCOSE TOLERANCE IMPAIRED 20 0.0034
111 PANCREATITIS CHRONIC 8 0.0034
112 ADRENAL INSUFFICIENCY 41 0.0034
113 SKIN INFECTION 36 0.0032
114 DRY SKIN 426 0.0032
115 PARANASAL SINUS DISCOMFORT 12 0.0032
116 PYODERMA GANGRENOSUM 11 0.0031
117 VITILIGO 7 0.0030
118 SKIN WARM 17 0.0029
119 SNORING 11 0.0029
120 ACUTE GRAFT VERSUS HOST DISEASE IN SKIN 8 0.0029
121 RASH PUSTULAR 21 0.0029
122 THYROID MASS 11 0.0029
123 BLEPHARITIS 11 0.0027
124 SKIN MASS 18 0.0027
125 RHINITIS ALLERGIC 12 0.0027
126 TRIGGER FINGER 11 0.0027
127 PLANTAR FASCIITIS 9 0.0027
128 SQUAMOUS CELL CARCINOMA 25 0.0027
129 APPLICATION SITE DRYNESS 9 0.0026
130 EYE PRURITUS 88 0.0026
131 SKIN DISORDER 87 0.0026
132 PIGMENTATION DISORDER 16 0.0026
133 PRURITUS 992 0.0026
134 THERAPEUTIC RESPONSE SHORTENED 84 0.0025
135 STAPHYLOCOCCAL BACTERAEMIA 11 0.0025
136 TRICHORRHEXIS 7 0.0025
137 PARONYCHIA 11 0.0025
138 NERVE COMPRESSION 23 0.0025
139 ENTEROCOCCAL INFECTION 12 0.0025
140 VULVOVAGINAL DRYNESS 8 0.0025
141 CUTANEOUS VASCULITIS 9 0.0025
142 DRY EYE 122 0.0024
143 SKIN LESION 67 0.0024
144 SKIN DISCOLOURATION 110 0.0024
145 SKIN TIGHTNESS 11 0.0023
146 SKIN ABRASION 11 0.0023
147 ORAL HERPES 45 0.0023
148 MULTIPLE ALLERGIES 18 0.0023
149 VULVOVAGINAL BURNING SENSATION 14 0.0023
150 ONYCHOMYCOSIS 10 0.0023
151 ORAL CANDIDIASIS 30 0.0023
152 RASH MACULAR 79 0.0023
153 PRODUCT USE IN UNAPPROVED INDICATION 559 0.0023
154 INFUSION SITE PRURITUS 7 0.0022
155 FEELING OF BODY TEMPERATURE CHANGE 13 0.0022
156 EYE DISCHARGE 23 0.0022
157 TENDERNESS 23 0.0022
158 FOLLICULITIS 23 0.0022
159 LACRIMATION INCREASED 66 0.0022
160 BUNDLE BRANCH BLOCK RIGHT 10 0.0022
161 DYSURIA 80 0.0022
162 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 119 0.0022
163 PRODUCT LEAKAGE 12 0.0021
164 POOR QUALITY SLEEP 46 0.0021
165 DERMATITIS ACNEIFORM 13 0.0021
166 INFUSION SITE HAEMORRHAGE 7 0.0021
167 SUSPECTED COVID-19 7 0.0021
168 PAIN OF SKIN 57 0.0021
169 LEFT VENTRICULAR HYPERTROPHY 9 0.0021
170 SENSITIVITY TO WEATHER CHANGE 11 0.0021
171 POLYARTHRITIS 11 0.0021
172 HORDEOLUM 9 0.0021
173 SEASONAL ALLERGY 29 0.0020
174 WOUND COMPLICATION 7 0.0020
175 CYTOMEGALOVIRUS INFECTION REACTIVATION 9 0.0020
176 INFUSION SITE ERYTHEMA 17 0.0020
177 EXPOSURE VIA SKIN CONTACT 52 0.0020
178 HERPES SIMPLEX 13 0.0020
179 FUNGAL SKIN INFECTION 8 0.0020
180 SKIN ULCER 51 0.0020
181 UPPER RESPIRATORY TRACT INFECTION 91 0.0020
182 APPLICATION SITE DISCOLOURATION 8 0.0020
183 HYPERURICAEMIA 8 0.0019
184 PERIORBITAL SWELLING 11 0.0019
185 BLISTER 109 0.0019
186 RASH PRURITIC 104 0.0019
187 SENSORY DISTURBANCE 30 0.0019
188 BURNING SENSATION 131 0.0019
189 TOOTH ABSCESS 19 0.0019
190 PNEUMONIA BACTERIAL 17 0.0019
191 ANTINUCLEAR ANTIBODY POSITIVE 6 0.0018
192 SKIN LACERATION 20 0.0018
193 CONJUNCTIVITIS 34 0.0018
194 INJECTION SITE VESICLES 11 0.0018
195 THERAPEUTIC PRODUCT INEFFECTIVE 7 0.0018
196 POOR QUALITY PRODUCT ADMINISTERED 19 0.0018
197 BASAL CELL CARCINOMA 28 0.0018
198 PRESCRIPTION DRUG USED WITHOUT A PRESCRIPTION 11 0.0018
199 DYSLIPIDAEMIA 9 0.0018
200 INITIAL INSOMNIA 18 0.0018
201 PSEUDOMONAS INFECTION 15 0.0017
202 PERIPHERAL COLDNESS 24 0.0017
203 SKIN PAPILLOMA 7 0.0017
204 VARICOSE VEIN 9 0.0017
205 JOINT EFFUSION 12 0.0017
206 RASH ERYTHEMATOUS 83 0.0017
207 ENTEROCOLITIS 10 0.0017
208 THERAPY PARTIAL RESPONDER 27 0.0017
209 VITAMIN B12 DEFICIENCY 7 0.0017
210 STAPHYLOCOCCAL INFECTION 57 0.0017
211 MATERNAL EXPOSURE DURING BREAST FEEDING 7 0.0017
212 SELF-MEDICATION 7 0.0017
213 HIP ARTHROPLASTY 26 0.0017
214 COMPRESSION FRACTURE 9 0.0017
215 LOW DENSITY LIPOPROTEIN INCREASED 13 0.0017
216 ERYTHEMA 345 0.0017
217 DERMATITIS ALLERGIC 21 0.0017
218 CELLULITIS 84 0.0017
219 SLEEP TERROR 7 0.0017
220 RASH VESICULAR 8 0.0017
221 VITAMIN D DEFICIENCY 16 0.0016
222 DRUG ERUPTION 29 0.0016
223 PYELONEPHRITIS 14 0.0016
224 ECCHYMOSIS 11 0.0016
225 DIVERTICULUM INTESTINAL 7 0.0016
226 EYE PAIN 90 0.0016
227 LYMPHOEDEMA 11 0.0016
228 INFUSION SITE SWELLING 10 0.0016
229 MULTIPLE INJURIES 10 0.0016
230 ECONOMIC PROBLEM 24 0.0016
231 LYMPHADENOPATHY 56 0.0016
232 RASH 687 0.0016
233 DEVICE DELIVERY SYSTEM ISSUE 43 0.0016
234 FOREIGN BODY SENSATION IN EYES 10 0.0016
235 FUNGAL INFECTION 52 0.0016
236 FOOD ALLERGY 12 0.0016
237 APPLICATION SITE VESICLES 10 0.0015
238 NEUTROPENIC SEPSIS 11 0.0015
239 INFLAMMATORY BOWEL DISEASE 15 0.0015
240 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 108 0.0015
241 PRODUCT FORMULATION ISSUE 10 0.0015
242 NEPHROGENIC ANAEMIA 7 0.0015
243 REBOUND EFFECT 17 0.0015
244 SYMPTOM RECURRENCE 9 0.0015
245 DEVICE RELATED INFECTION 23 0.0015
246 INCORRECT DRUG ADMINISTRATION DURATION 42 0.0015
247 JOINT RANGE OF MOTION DECREASED 20 0.0015
248 SENSITIVE SKIN 11 0.0015
249 NAIL DISORDER 13 0.0015
250 ARTHROPOD BITE 11 0.0015
251 EOSINOPHILIA 26 0.0015
252 ERYTHEMA OF EYELID 8 0.0015
253 SUNBURN 11 0.0015
254 EYE INFLAMMATION 14 0.0015
255 APPLICATION SITE EXFOLIATION 6 0.0015
256 APPLICATION SITE PRURITUS 33 0.0015
257 OCULAR HYPERAEMIA 69 0.0015
258 CHOLANGITIS 9 0.0015
259 THERAPEUTIC RESPONSE DECREASED 87 0.0014
260 EYE SWELLING 53 0.0014
261 HYPERLIPIDAEMIA 17 0.0014
262 DUODENAL ULCER 10 0.0014
263 HYPERVOLAEMIA 7 0.0014
264 AORTIC VALVE INCOMPETENCE 6 0.0014
265 GAIT INABILITY 47 0.0014
266 PRODUCT DISTRIBUTION ISSUE 13 0.0014
267 VEIN DISORDER 7 0.0014
268 DERMATITIS EXFOLIATIVE 7 0.0014
269 SKIN HYPERPIGMENTATION 12 0.0014
270 ERYSIPELAS 7 0.0014
271 VULVOVAGINAL PRURITUS 7 0.0014
272 PRODUCT DOSE OMISSION IN ERROR 39 0.0014
273 LIQUID PRODUCT PHYSICAL ISSUE 10 0.0014
274 SINUS DISORDER 27 0.0014
275 INJECTION SITE DISCOLOURATION 17 0.0014
276 MUSCULOSKELETAL CHEST PAIN 21 0.0014
277 FAILURE TO THRIVE 7 0.0013
278 TONSILLITIS 7 0.0013
279 OCULAR DISCOMFORT 15 0.0013
280 SINUS CONGESTION 18 0.0013
281 PHOTOSENSITIVITY REACTION 22 0.0013
282 EXPIRED PRODUCT ADMINISTERED 44 0.0013
283 WOUND 37 0.0013
284 DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 34 0.0013
285 INFUSION SITE PAIN 17 0.0013
286 OSTEOPENIA 20 0.0013
287 HIDRADENITIS 12 0.0013
288 LIGAMENT SPRAIN 13 0.0013
289 CROHN'S DISEASE 9 0.0013
290 SKIN BURNING SENSATION 94 0.0013
291 HAIR GROWTH ABNORMAL 9 0.0013
292 LARGE INTESTINE POLYP 9 0.0013
293 INTENTIONAL DOSE OMISSION 37 0.0013
294 THERAPEUTIC PRODUCT EFFECT DECREASED 58 0.0013
295 RASH PAPULAR 29 0.0013
296 CHEILITIS 7 0.0013
297 HAIR COLOUR CHANGES 16 0.0013
298 DRY THROAT 13 0.0013
299 MUSCULOSKELETAL DISCOMFORT 22 0.0013
300 BRAIN FOG 20 0.0013
301 LACERATION 12 0.0013
302 SLEEP DISORDER 90 0.0013
303 ARTERIOSCLEROSIS 12 0.0013
304 MALIGNANT MELANOMA 17 0.0013
305 EAR DISCOMFORT 13 0.0013
306 FURUNCLE 10 0.0013
307 TRICUSPID VALVE INCOMPETENCE 10 0.0013
308 GINGIVAL PAIN 10 0.0013
309 MACULAR DEGENERATION 15 0.0013
310 SCIATICA 20 0.0013
311 GRAFT VERSUS HOST DISEASE 9 0.0013
312 HYPERCHOLESTEROLAEMIA 12 0.0012
313 NEUROPATHY PERIPHERAL 118 0.0012
314 EYE INFECTION 14 0.0012
315 KNEE ARTHROPLASTY 26 0.0012
316 POST PROCEDURAL INFECTION 10 0.0012
317 APPLICATION SITE ERYTHEMA 32 0.0012
318 UPPER-AIRWAY COUGH SYNDROME 10 0.0012
319 HAIR DISORDER 10 0.0012
320 MOUTH SWELLING 7 0.0012
321 EXOSTOSIS 11 0.0012
322 INJECTION SITE SWELLING 92 0.0012
323 GLAUCOMA 23 0.0012
324 MOUTH ULCERATION 25 0.0012
325 CONTUSION 114 0.0012
326 SINUS HEADACHE 7 0.0012
327 INSURANCE ISSUE 18 0.0012
328 BOWEL MOVEMENT IRREGULARITY 9 0.0012
329 INJECTION SITE RASH 36 0.0012
330 ROTATOR CUFF SYNDROME 15 0.0012
331 EYE IRRITATION 67 0.0012
332 RESPIRATION ABNORMAL 8 0.0012
333 APHTHOUS ULCER 9 0.0012
334 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 209 0.0012
335 BLOOD MAGNESIUM DECREASED 10 0.0012
336 MUSCLE STRAIN 10 0.0012
337 OSTEOARTHRITIS 49 0.0012
338 CARDIAC MURMUR 10 0.0012
339 SLEEP APNOEA SYNDROME 22 0.0012
340 NEURALGIA 28 0.0012
341 NODULE 15 0.0011
342 PERIPHERAL SWELLING 177 0.0011
343 MITRAL VALVE INCOMPETENCE 13 0.0011
344 TREATMENT FAILURE 95 0.0011
345 PRODUCT ADMINISTRATION INTERRUPTED 9 0.0011
346 ILLNESS 118 0.0011
347 CARPAL TUNNEL SYNDROME 16 0.0011
348 PULMONARY MASS 17 0.0011
349 INJECTION SITE DISCOMFORT 12 0.0011
350 IMMUNODEFICIENCY 17 0.0011
351 SPINAL OSTEOARTHRITIS 10 0.0011
352 RENAL CYST 9 0.0011
353 ULCER 18 0.0011
354 LYMPHOPENIA 16 0.0011
355 APPLICATION SITE IRRITATION 14 0.0011
356 INFUSION SITE EXTRAVASATION 7 0.0011
357 NASAL CONGESTION 66 0.0011
358 SINUSITIS 115 0.0011
359 FEAR OF INJECTION 8 0.0011
360 PRE-EXISTING CONDITION IMPROVED 7 0.0011
361 CONDITION AGGRAVATED 340 0.0011
362 NASAL DRYNESS 7 0.0011
363 SWELLING OF EYELID 7 0.0011
364 SNEEZING 25 0.0011
365 SCAR 19 0.0011
366 PRODUCT DOSE OMISSION ISSUE 326 0.0011
367 INCORRECT PRODUCT ADMINISTRATION DURATION 24 0.0011
368 BACK DISORDER 18 0.0011
369 VISUAL FIELD DEFECT 8 0.0011
370 INJECTION SITE PAIN 338 0.0011
371 COVID-19 PNEUMONIA 13 0.0011
372 INJECTION SITE URTICARIA 27 0.0011
373 INJECTION SITE IRRITATION 14 0.0011
374 MAJOR DEPRESSION 8 0.0011
375 SKIN IRRITATION 50 0.0011
376 EAR INFECTION 29 0.0011
377 FOOT DEFORMITY 12 0.0011
378 LOWER GASTROINTESTINAL HAEMORRHAGE 8 0.0011
379 INTERVERTEBRAL DISC DEGENERATION 10 0.0011
380 DRUG EFFECT LESS THAN EXPECTED 16 0.0011
381 ANGINA UNSTABLE 7 0.0011
382 ORAL PAIN 24 0.0011
383 RESPIRATORY TRACT CONGESTION 17 0.0011
384 LIMB INJURY 29 0.0011
385 CANDIDA INFECTION 18 0.0011
386 SKIN REACTION 15 0.0011
387 IMMUNE SYSTEM DISORDER 14 0.0011
388 STOMATITIS 64 0.0011
389 VITAMIN D DECREASED 9 0.0011
390 PRODUCT PACKAGING ISSUE 10 0.0011
391 WEIGHT FLUCTUATION 11 0.0011
392 PHARYNGITIS 13 0.0010
393 HAIR TEXTURE ABNORMAL 14 0.0010
394 POST-TRAUMATIC STRESS DISORDER 7 0.0010
395 CATARACT 62 0.0010
396 CLOSTRIDIUM DIFFICILE COLITIS 11 0.0010
397 POSTOPERATIVE WOUND INFECTION 7 0.0010
398 BRONCHOPULMONARY ASPERGILLOSIS 8 0.0010
399 IMPAIRED GASTRIC EMPTYING 14 0.0010
400 MATERNAL EXPOSURE BEFORE PREGNANCY 7 0.0010
401 PULMONARY HAEMORRHAGE 8 0.0010
402 SKIN CANCER 22 0.0010
403 HEPATIC STEATOSIS 19 0.0010
404 PHARYNGITIS STREPTOCOCCAL 11 0.0010
405 PRODUCT USE COMPLAINT 16 0.0010
406 ARTHRALGIA 422 0.0010
407 URTICARIA 170 0.0010
408 RENAL DISORDER 47 0.0010
409 HAEMATOCRIT DECREASED 20 0.0010
410 BLOOD SODIUM DECREASED 19 0.0010
411 BLADDER DISORDER 10 0.0010
412 FEELING COLD 28 0.0010
413 GASTROINTESTINAL INFECTION 9 0.0010
414 MYOSITIS 9 0.0010
415 LIMB DISCOMFORT 31 0.0010
416 MASS 14 0.0010
417 HYPOTONIA 10 0.0010
418 INJECTION SITE PRURITUS 67 0.0010
419 RESPIRATORY TRACT INFECTION 26 0.0010
420 OROPHARYNGEAL DISCOMFORT 9 0.0010
421 NIGHT SWEATS 32 0.0010
422 TOXIC SKIN ERUPTION 10 0.0010
423 RHINITIS 8 0.0010
424 NOCTURIA 12 0.0010
425 HAND FRACTURE 7 0.0010
426 ALOPECIA 194 0.0010
427 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 18 0.0010
428 NEUTROPHIL COUNT INCREASED 10 0.0010
429 ESCHERICHIA INFECTION 8 0.0010
430 RIB FRACTURE 20 0.0010
431 TEMPERATURE INTOLERANCE 10 0.0010
432 ARTHRITIS 76 0.0010
433 ERYTHEMA MULTIFORME 9 0.0010
434 MIDDLE INSOMNIA 18 0.0010
435 PAIN IN EXTREMITY 284 0.0010
436 FLANK PAIN 9 0.0010
437 BRONCHITIS 71 0.0010
438 UPPER LIMB FRACTURE 19 0.0010
439 JOINT STIFFNESS 25 0.0010
440 ACCIDENTAL EXPOSURE TO PRODUCT 98 0.0009
441 GASTRITIS 25 0.0009
442 FOOT FRACTURE 18 0.0009
443 APPLICATION SITE RASH 13 0.0009
444 SUDDEN DEATH 10 0.0009
445 TOOTH DISORDER 21 0.0009
446 FEELING DRUNK 7 0.0009
447 LEUKOPENIA 47 0.0009
448 SPINAL PAIN 11 0.0009
449 RETCHING 20 0.0009
450 SINUS BRADYCARDIA 9 0.0009
451 SYNCOPE 93 0.0009
452 BACTERAEMIA 11 0.0009
453 PRODUCT PRESCRIBING ERROR 22 0.0009
454 TOXIC EPIDERMAL NECROLYSIS 14 0.0009
455 RESPIRATORY SYNCYTIAL VIRUS INFECTION 8 0.0009
456 RHINORRHOEA 59 0.0009
457 HOSPICE CARE 9 0.0009
458 TOOTH INFECTION 12 0.0009
459 PRODUCT USE ISSUE 171 0.0009
460 GRIP STRENGTH DECREASED 8 0.0009
461 IMMUNOSUPPRESSION 8 0.0009
462 BURSITIS 11 0.0009
463 ARTERIOSCLEROSIS CORONARY ARTERY 6 0.0009
464 IMPAIRED QUALITY OF LIFE 13 0.0009
465 PURPURA 8 0.0009
466 DENTAL CARIES 10 0.0009
467 URINARY TRACT INFECTION 154 0.0009
468 CYTOMEGALOVIRUS INFECTION 15 0.0009
469 HOT FLUSH 68 0.0009
470 PARAESTHESIA ORAL 13 0.0009
471 COAGULOPATHY 15 0.0009
472 RASH MACULO-PAPULAR 20 0.0009
473 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 43 0.0009
474 HEPATIC ENZYME INCREASED 61 0.0009
475 NECK PAIN 50 0.0009
476 MOBILITY DECREASED 64 0.0009
477 HYPOGLYCAEMIA 43 0.0009
478 HEART RATE DECREASED 31 0.0009
479 HYPOACUSIS 38 0.0009
480 PELVIC PAIN 16 0.0009
481 MICTURITION URGENCY 10 0.0009
482 OSTEOPOROSIS 36 0.0009
483 HAEMORRHOIDS 17 0.0009
484 INCREASED TENDENCY TO BRUISE 8 0.0009
485 IRON DEFICIENCY ANAEMIA 8 0.0009
486 DIVERTICULITIS 24 0.0009
487 DEPRESSION 197 0.0009
488 DIABETES MELLITUS 66 0.0009
489 BLOOD POTASSIUM DECREASED 26 0.0009
490 INSOMNIA 230 0.0009
491 ELECTROLYTE IMBALANCE 10 0.0009
492 DIARRHOEA HAEMORRHAGIC 8 0.0009
493 BLOOD TEST ABNORMAL 12 0.0009
494 EYE DISORDER 28 0.0009
495 INCONTINENCE 9 0.0009
496 DRUG INEFFECTIVE 1121 0.0008
497 MYALGIA 144 0.0008
498 OEDEMA PERIPHERAL 103 0.0008
499 SPINAL DISORDER 8 0.0008
500 PLATELET COUNT INCREASED 11 0.0008
501 BACK PAIN 196 0.0008
502 INJECTION SITE BRUISING 67 0.0008
503 POLLAKIURIA 35 0.0008
504 COVID-19 147 0.0008
505 POST PROCEDURAL COMPLICATION 16 0.0008
506 INJECTION SITE ERYTHEMA 103 0.0008
507 ATELECTASIS 8 0.0008
508 BIPOLAR DISORDER 9 0.0008
509 INFLUENZA 92 0.0008
510 IMPAIRED HEALING 27 0.0008
511 HEAD INJURY 26 0.0008
512 MUSCULAR WEAKNESS 93 0.0008
513 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 14 0.0008
514 TOOTH FRACTURE 9 0.0008
515 INFLUENZA LIKE ILLNESS 67 0.0008
516 INJECTION SITE MASS 30 0.0008
517 INTENTIONAL PRODUCT MISUSE 71 0.0008
518 INFECTION 117 0.0008
519 DEVICE DEFECTIVE 14 0.0008
520 HEADACHE 505 0.0008
521 MUSCLE TIGHTNESS 13 0.0008
522 TYPE 2 DIABETES MELLITUS 27 0.0008
523 VISION BLURRED 110 0.0008
524 THERAPY NON-RESPONDER 36 0.0008
525 BLOOD CALCIUM DECREASED 9 0.0008
526 PEMPHIGUS 10 0.0008
527 PRODUCTIVE COUGH 38 0.0008
528 BLOOD TRIGLYCERIDES INCREASED 14 0.0008
529 ACNE 60 0.0008
530 FALL 263 0.0008
531 OROPHARYNGEAL PAIN 73 0.0008
532 CHOLECYSTECTOMY 9 0.0008
533 DYSSTASIA 23 0.0008
534 HYPERSENSITIVITY 146 0.0008
535 OFF LABEL USE 687 0.0008
536 THIRST 14 0.0008
537 HERPES ZOSTER 45 0.0008
538 GASTROOESOPHAGEAL REFLUX DISEASE 63 0.0008
539 DRUG PRESCRIBING ERROR 15 0.0008
540 PRODUCT PRESCRIBING ISSUE 17 0.0008
541 CLOSTRIDIUM DIFFICILE INFECTION 17 0.0008
542 JOINT SWELLING 94 0.0008
543 WEIGHT DECREASED 217 0.0008
544 MIGRAINE 74 0.0008
545 SINUS TACHYCARDIA 11 0.0008
546 ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS 6 0.0008
547 INJECTION SITE INDURATION 10 0.0008
548 PNEUMONITIS 21 0.0008
549 FEELING HOT 47 0.0008
550 CHRONIC KIDNEY DISEASE 58 0.0008
551 BEDRIDDEN 10 0.0008
552 CONTRAINDICATED PRODUCT ADMINISTERED 23 0.0008
553 NASOPHARYNGITIS 140 0.0008
554 HYPOKALAEMIA 35 0.0008
555 GASTROENTERITIS 11 0.0008
556 OBESITY 12 0.0008
557 EATING DISORDER 16 0.0008
558 ABDOMINAL DISCOMFORT 126 0.0008
559 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 22 0.0008
560 LIP SWELLING 25 0.0007
561 BODY HEIGHT DECREASED 8 0.0007
562 MUSCLE SPASMS 137 0.0007
563 LIVER FUNCTION TEST INCREASED 16 0.0007
564 LOCALISED INFECTION 18 0.0007
565 C-REACTIVE PROTEIN INCREASED 27 0.0007
566 NEPHROLITHIASIS 34 0.0007
567 FEEDING DISORDER 15 0.0007
568 TASTE DISORDER 15 0.0007
569 SWELLING FACE 48 0.0007
570 SWOLLEN TONGUE 23 0.0007
571 FEELING JITTERY 14 0.0007
572 HEAD DISCOMFORT 13 0.0007
573 OESOPHAGITIS 8 0.0007
574 INTERVERTEBRAL DISC PROTRUSION 16 0.0007
575 SPINAL OPERATION 9 0.0007
576 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 17 0.0007
577 HYPOAESTHESIA 109 0.0007
578 WRONG TECHNIQUE IN DEVICE USAGE PROCESS 34 0.0007
579 GASTROINTESTINAL PAIN 8 0.0007
580 INJECTION SITE REACTION 50 0.0007
581 CYST 9 0.0007
582 BLOOD ALKALINE PHOSPHATASE INCREASED 18 0.0007
583 COUGH 203 0.0007
584 ANXIETY 206 0.0007
585 GAIT DISTURBANCE 138 0.0007
586 PRODUCT DOSE OMISSION 47 0.0007
587 OEDEMA 39 0.0007
588 EXTRA DOSE ADMINISTERED 29 0.0007
589 RESTLESS LEGS SYNDROME 13 0.0007
590 GLYCOSYLATED HAEMOGLOBIN INCREASED 18 0.0007
591 SEPTIC SHOCK 31 0.0007
592 HAEMATEMESIS 18 0.0007
593 BLOOD PRESSURE DECREASED 47 0.0007
594 PAIN IN JAW 20 0.0007
595 DIARRHOEA 453 0.0007
596 OVARIAN CYST 7 0.0007
597 DEPRESSED MOOD 37 0.0007
598 IRRITABLE BOWEL SYNDROME 15 0.0007
599 SURGERY 41 0.0007
600 SPINAL FRACTURE 14 0.0007
601 PANCYTOPENIA 39 0.0007
602 BLOOD LACTATE DEHYDROGENASE INCREASED 11 0.0007
603 EMPHYSEMA 7 0.0007
604 VIRAL INFECTION 23 0.0007
605 ABSCESS 11 0.0007
606 HYPERTENSION 146 0.0007
607 INJECTION SITE HAEMATOMA 10 0.0007
608 PRODUCT DISPENSING ERROR 15 0.0007
609 COMPLICATION ASSOCIATED WITH DEVICE 10 0.0007
610 FATIGUE 536 0.0007
611 DISCOMFORT 42 0.0007
612 DEAFNESS 18 0.0007
613 VASCULITIS 8 0.0007
614 ANHEDONIA 18 0.0007
615 ARTHROPATHY 38 0.0007
616 ANKYLOSING SPONDYLITIS 9 0.0007
617 SEXUAL DYSFUNCTION 8 0.0007
618 SARS-COV-2 TEST POSITIVE 9 0.0007
619 BLOOD PRESSURE INCREASED 104 0.0007
620 WHITE BLOOD CELL COUNT INCREASED 26 0.0007
621 BLOOD POTASSIUM INCREASED 11 0.0007
622 POOR VENOUS ACCESS 7 0.0007
623 TINNITUS 31 0.0007
624 EYE HAEMORRHAGE 9 0.0007
625 BLOOD IRON DECREASED 8 0.0007
626 PYREXIA 233 0.0007
627 GALLBLADDER DISORDER 12 0.0007
628 PULMONARY HYPERTENSION 14 0.0007
629 ANAPHYLACTIC REACTION 37 0.0007
630 GOUT 12 0.0007
631 EAR PAIN 13 0.0007
632 HYPERHIDROSIS 86 0.0007
633 PAIN 410 0.0007
634 DRY MOUTH 54 0.0007
635 GASTROENTERITIS VIRAL 12 0.0007
636 CHROMATURIA 15 0.0007
637 CHEST DISCOMFORT 68 0.0007
638 HEPATIC FAILURE 20 0.0007
639 INTESTINAL OBSTRUCTION 25 0.0007
640 DECREASED APPETITE 154 0.0007
641 TOOTHACHE 12 0.0007
642 SWELLING 62 0.0007
643 INFLAMMATION 34 0.0007
644 BLOOD UREA INCREASED 11 0.0007
645 RASH GENERALISED 17 0.0007
646 HEREDITARY ANGIOEDEMA 7 0.0007
647 MUSCLE SPASTICITY 8 0.0007
648 INJECTION SITE EXTRAVASATION 8 0.0006
649 ORAL DISCOMFORT 9 0.0006
650 THERAPEUTIC RESPONSE UNEXPECTED 29 0.0006
651 AGRANULOCYTOSIS 12 0.0006
652 HAEMOPTYSIS 18 0.0006
653 BLOOD CHOLESTEROL INCREASED 30 0.0006
654 PRODUCT ADMINISTRATION ERROR 13 0.0006
655 BACTERIAL INFECTION 12 0.0006
656 URINARY INCONTINENCE 19 0.0006
657 CHOLELITHIASIS 21 0.0006
658 TUBULOINTERSTITIAL NEPHRITIS 12 0.0006
659 VERTIGO 39 0.0006
660 SECRETION DISCHARGE 8 0.0006
661 BLINDNESS UNILATERAL 9 0.0006
662 DRUG-INDUCED LIVER INJURY 20 0.0006
663 BONE PAIN 37 0.0006
664 MUSCULOSKELETAL DISORDER 12 0.0006
665 TRANSAMINASES INCREASED 14 0.0006
666 NERVE INJURY 7 0.0006
667 HYPERTENSIVE CRISIS 7 0.0006
668 EPISTAXIS 47 0.0006
669 CORONARY ARTERY DISEASE 19 0.0006
670 PULMONARY FIBROSIS 12 0.0006
671 ERECTILE DYSFUNCTION 16 0.0006
672 PANCREATITIS ACUTE 14 0.0006
673 HERNIA 12 0.0006
674 HEART RATE IRREGULAR 14 0.0006
675 HAEMATOMA 16 0.0006
676 DIPLOPIA 16 0.0006
677 PALPITATIONS 72 0.0006
678 PNEUMONIA 198 0.0006
679 DYSPNOEA EXERTIONAL 23 0.0006
680 PULMONARY EMBOLISM 58 0.0006
681 METASTASES TO BONE 10 0.0006
682 NEOPLASM 7 0.0006
683 NIGHTMARE 21 0.0006
684 PULMONARY CONGESTION 8 0.0006
685 HYPERGLYCAEMIA 22 0.0006
686 DIZZINESS 301 0.0006
687 FEBRILE NEUTROPENIA 40 0.0006
688 PULMONARY OEDEMA 27 0.0006
689 WEIGHT INCREASED 135 0.0006
690 GASTROINTESTINAL DISORDER 54 0.0006
691 AGEUSIA 15 0.0006
692 PRURITUS GENERALISED 13 0.0006
693 RESTLESSNESS 22 0.0006
694 SEPSIS 67 0.0006
695 CHEST PAIN 111 0.0006
696 BREAST CANCER FEMALE 16 0.0006
697 ROAD TRAFFIC ACCIDENT 25 0.0006
698 CYSTITIS 19 0.0006
699 ASTHMA 67 0.0006
700 THROAT TIGHTNESS 16 0.0006
701 BALANCE DISORDER 51 0.0006
702 UVEITIS 8 0.0006
703 DRUG DISPENSING ERROR 9 0.0006
704 RENAL FAILURE 78 0.0006
705 AKATHISIA 8 0.0006
706 HYPONATRAEMIA 33 0.0006
707 PARAESTHESIA 92 0.0006
708 WRIST FRACTURE 7 0.0006
709 ASTHENIA 219 0.0006
710 ACUTE KIDNEY INJURY 89 0.0006
711 ANKLE FRACTURE 9 0.0006
712 DYSPHONIA 34 0.0006
713 DYSPEPSIA 57 0.0006
714 OSTEONECROSIS 19 0.0006
715 ACUTE MYOCARDIAL INFARCTION 17 0.0006
716 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 41 0.0006
717 MENTAL STATUS CHANGES 16 0.0006
718 DISEASE PROGRESSION 68 0.0006
719 HUNGER 8 0.0006
720 NO THERAPEUTIC RESPONSE 7 0.0006
721 CYTOPENIA 7 0.0006
722 DEHYDRATION 76 0.0006
723 CARDIOMEGALY 7 0.0006
724 DEVICE OCCLUSION 8 0.0006
725 RESPIRATORY DISORDER 17 0.0006
726 FEELING ABNORMAL 136 0.0006
727 PNEUMOTHORAX 9 0.0006
728 COLD SWEAT 10 0.0006
729 NAUSEA 449 0.0006
730 GENERALISED OEDEMA 7 0.0006
731 HAEMOGLOBIN DECREASED 58 0.0006
732 DIABETES MELLITUS INADEQUATE CONTROL 10 0.0006
733 ASPARTATE AMINOTRANSFERASE INCREASED 30 0.0006
734 FLATULENCE 32 0.0006
735 TOOTH EXTRACTION 7 0.0006
736 PERICARDIAL EFFUSION 13 0.0006
737 DYSPNOEA 317 0.0006
738 PRODUCT QUALITY ISSUE 76 0.0006
739 COLITIS ULCERATIVE 25 0.0006
740 RECTAL HAEMORRHAGE 24 0.0006
741 ANGINA PECTORIS 16 0.0006
742 HYPERSOMNIA 16 0.0006
743 WHEEZING 33 0.0006
744 LETHARGY 32 0.0006
745 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 29 0.0006
746 FREQUENT BOWEL MOVEMENTS 15 0.0006
747 DEEP VEIN THROMBOSIS 36 0.0006
748 BLOOD PRESSURE ABNORMAL 11 0.0006
749 LOWER RESPIRATORY TRACT INFECTION 25 0.0005
750 END STAGE RENAL DISEASE 10 0.0005
751 INTRAOCULAR PRESSURE INCREASED 7 0.0005
752 HYPOPHAGIA 14 0.0005
753 FULL BLOOD COUNT DECREASED 11 0.0005
754 ABNORMAL DREAMS 15 0.0005
755 CONSTIPATION 118 0.0005
756 FLUSHING 55 0.0005
757 DISTURBANCE IN ATTENTION 29 0.0005
758 ALANINE AMINOTRANSFERASE INCREASED 33 0.0005
759 INTENTIONAL PRODUCT USE ISSUE 47 0.0005
760 MUSCULOSKELETAL STIFFNESS 47 0.0005
761 GLOSSODYNIA 12 0.0005
762 HEPATIC FUNCTION ABNORMAL 20 0.0005
763 INJECTION SITE WARMTH 11 0.0005
764 FIBROMYALGIA 13 0.0005
765 PRESYNCOPE 13 0.0005
766 ABDOMINAL PAIN UPPER 110 0.0005
767 TRANSIENT ISCHAEMIC ATTACK 18 0.0005
768 HEPATIC CIRRHOSIS 10 0.0005
769 MOVEMENT DISORDER 17 0.0005
770 UNEVALUABLE EVENT 40 0.0005
771 PRODUCT AVAILABILITY ISSUE 12 0.0005
772 VISUAL IMPAIRMENT 65 0.0005
773 INCREASED APPETITE 10 0.0005
774 MYOCARDIAL INFARCTION 91 0.0005
775 DRUG ADMINISTRATION ERROR 16 0.0005
776 MALAISE 228 0.0005
777 ACUTE RESPIRATORY FAILURE 10 0.0005
778 EMOTIONAL DISORDER 16 0.0005
779 TACHYCARDIA 46 0.0005
780 NEOPLASM PROGRESSION 18 0.0005
781 INTERSTITIAL LUNG DISEASE 25 0.0005
782 DYSPHAGIA 49 0.0005
783 OXYGEN SATURATION DECREASED 29 0.0005
784 LOCAL SWELLING 9 0.0005
785 LIVER FUNCTION TEST ABNORMAL 15 0.0005
786 JOINT INJURY 11 0.0005
787 EJECTION FRACTION DECREASED 8 0.0005
788 ANAEMIA 98 0.0005
789 THROAT IRRITATION 23 0.0005
790 HYPOXIA 18 0.0005
791 VOMITING 240 0.0005
792 CORONARY ARTERY OCCLUSION 7 0.0005
793 KIDNEY INFECTION 10 0.0005
794 URINARY RETENTION 17 0.0005
795 LYMPHOCYTE COUNT DECREASED 9 0.0005
796 PROSTATIC SPECIFIC ANTIGEN INCREASED 7 0.0005
797 ABDOMINAL DISTENSION 53 0.0005
798 RENAL INJURY 15 0.0005
799 DISORIENTATION 20 0.0005
800 PROCEDURAL PAIN 14 0.0005
801 ACCIDENT 6 0.0005
802 HYPOTHYROIDISM 16 0.0005
803 INJECTION SITE HAEMORRHAGE 40 0.0005
804 PRODUCT PHYSICAL ISSUE 10 0.0005
805 TREATMENT NONCOMPLIANCE 27 0.0005
806 INCORRECT DOSE ADMINISTERED 112 0.0005
807 ABDOMINAL PAIN 114 0.0005
808 VAGINAL HAEMORRHAGE 21 0.0005
809 DISEASE RECURRENCE 23 0.0005
810 INFUSION RELATED REACTION 32 0.0005
811 DRUG EFFECT DECREASED 26 0.0005
812 MEMORY IMPAIRMENT 66 0.0005
813 PHOTOPHOBIA 9 0.0005
814 MUSCULOSKELETAL PAIN 25 0.0005
815 PLEURAL EFFUSION 29 0.0005
816 THERAPY INTERRUPTED 34 0.0005
817 UPPER GASTROINTESTINAL HAEMORRHAGE 8 0.0005
818 COLITIS 18 0.0005
819 FACE OEDEMA 8 0.0005
820 ABORTION SPONTANEOUS 19 0.0005
821 PANCREATITIS 25 0.0005
822 THROMBOSIS 38 0.0005
823 HEMIPARESIS 8 0.0005
824 MOOD SWINGS 15 0.0005
825 PLATELET COUNT DECREASED 50 0.0005
826 PANIC ATTACK 17 0.0005
827 HIP FRACTURE 15 0.0005
828 UNRESPONSIVE TO STIMULI 12 0.0005
829 ATRIAL FIBRILLATION 45 0.0005
830 WHITE BLOOD CELL COUNT DECREASED 50 0.0005
831 ORTHOSTATIC HYPOTENSION 8 0.0005
832 HAEMORRHAGE 48 0.0005
833 DISABILITY 9 0.0005
834 RED BLOOD CELL COUNT DECREASED 13 0.0005
835 MENTAL IMPAIRMENT 11 0.0005
836 LYMPHOMA 7 0.0005
837 ADVERSE REACTION 6 0.0005
838 PRESCRIBED UNDERDOSE 9 0.0005
839 HEPATOTOXICITY 10 0.0004
840 CYTOKINE RELEASE SYNDROME 9 0.0004
841 CHILLS 52 0.0004
842 LEUKOCYTOSIS 8 0.0004
843 OSTEOMYELITIS 8 0.0004
844 DRUG EFFECT INCOMPLETE 16 0.0004
845 CRYING 16 0.0004
846 PRODUCT PREPARATION ERROR 9 0.0004
847 GASTRIC DISORDER 15 0.0004
848 ABDOMINAL PAIN LOWER 11 0.0004
849 TOOTH LOSS 9 0.0004
850 HEART RATE INCREASED 43 0.0004
851 APHONIA 6 0.0004
852 LUNG DISORDER 21 0.0004
853 RENAL IMPAIRMENT 36 0.0004
854 NERVOUSNESS 22 0.0004
855 PROTEINURIA 8 0.0004
856 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 85 0.0004
857 LOWER LIMB FRACTURE 8 0.0004
858 DEVICE ISSUE 37 0.0004
859 CEREBRAL INFARCTION 10 0.0004
860 MELAENA 9 0.0004
861 ASCITES 12 0.0004
862 GAMMA-GLUTAMYLTRANSFERASE INCREASED 9 0.0004
863 LIVER DISORDER 18 0.0004
864 MULTI-ORGAN FAILURE 7 0.0004
865 NEOPLASM MALIGNANT 27 0.0004
866 ACTIVITIES OF DAILY LIVING IMPAIRED 8 0.0004
867 SYRINGE ISSUE 7 0.0004
868 HYPERKALAEMIA 14 0.0004
869 IRRITABILITY 24 0.0004
870 HALLUCINATION 30 0.0004
871 NEUTROPENIA 54 0.0004
872 BLOOD GLUCOSE DECREASED 19 0.0004
873 ILL-DEFINED DISORDER 24 0.0004
874 MATERNAL EXPOSURE DURING PREGNANCY 35 0.0004
875 MUSCLE TWITCHING 9 0.0004
876 CONFUSIONAL STATE 63 0.0004
877 PLASMA CELL MYELOMA 15 0.0004
878 AMNESIA 25 0.0004
879 BONE DISORDER 7 0.0004
880 HYPOTENSION 77 0.0004
881 SOMNOLENCE 77 0.0004
882 PRODUCT SUBSTITUTION ISSUE 22 0.0004
883 DEPRESSED LEVEL OF CONSCIOUSNESS 15 0.0004
884 BLOOD GLUCOSE ABNORMAL 7 0.0004
885 ADVERSE DRUG REACTION 34 0.0004
886 RENAL FAILURE ACUTE 16 0.0004
887 BLOOD PRESSURE FLUCTUATION 9 0.0004
888 CARDIAC DISORDER 35 0.0004
889 CARDIAC FAILURE CONGESTIVE 30 0.0004
890 FEAR 10 0.0004
891 BLOOD BILIRUBIN INCREASED 10 0.0004
892 NEUTROPHIL COUNT DECREASED 15 0.0004
893 MENTAL DISORDER 16 0.0004
894 MOOD ALTERED 10 0.0004
895 SYSTEMIC LUPUS ERYTHEMATOSUS 13 0.0004
896 CHOLESTASIS 7 0.0004
897 ABASIA 9 0.0004
898 EMOTIONAL DISTRESS 44 0.0004
899 SPEECH DISORDER 19 0.0004
900 HAEMATOCHEZIA 20 0.0004
901 DRUG INTOLERANCE 35 0.0004
902 CEREBROVASCULAR ACCIDENT 61 0.0004
903 STEVENS-JOHNSON SYNDROME 8 0.0004
904 FLUID RETENTION 18 0.0004
905 MULTIPLE ORGAN DYSFUNCTION SYNDROME 10 0.0004
906 DYSARTHRIA 13 0.0003
907 NEEDLE ISSUE 10 0.0003
908 RHEUMATOID ARTHRITIS 39 0.0003
909 TREMOR 57 0.0003
910 BODY TEMPERATURE INCREASED 7 0.0003
911 AMENORRHOEA 6 0.0003
912 INJURY 24 0.0003
913 DRUG INTERACTION 54 0.0003
914 LOSS OF CONSCIOUSNESS 43 0.0003
915 BLOOD GLUCOSE INCREASED 63 0.0003
916 WITHDRAWAL SYNDROME 14 0.0003
917 THERAPY CESSATION 17 0.0003
918 VISUAL ACUITY REDUCED 11 0.0003
919 THROMBOCYTOPENIA 37 0.0003
920 RESPIRATORY DISTRESS 9 0.0003
921 ANGER 11 0.0003
922 CARDIAC FAILURE 26 0.0003
923 DEMENTIA 9 0.0003
924 COGNITIVE DISORDER 15 0.0003
925 DYSKINESIA 13 0.0003
926 PRODUCT STORAGE ERROR 28 0.0003
927 BLINDNESS 13 0.0003
928 DELIRIUM 11 0.0003
929 SUICIDAL IDEATION 29 0.0003
930 LUNG NEOPLASM MALIGNANT 13 0.0003
931 MULTIPLE SCLEROSIS 15 0.0003
932 HEPATITIS 8 0.0003
933 HOSPITALISATION 48 0.0003
934 DRUG RESISTANCE 8 0.0003
935 WRONG TECHNIQUE IN DRUG USAGE PROCESS 11 0.0003
936 RESPIRATORY FAILURE 22 0.0003
937 APHASIA 9 0.0003
938 DYSGEUSIA 22 0.0003
939 ARRHYTHMIA 14 0.0003
940 GENERAL PHYSICAL HEALTH DETERIORATION 34 0.0003
941 ADVERSE EVENT 27 0.0003
942 DIABETIC KETOACIDOSIS 7 0.0003
943 NERVOUS SYSTEM DISORDER 9 0.0003
944 GASTROINTESTINAL HAEMORRHAGE 24 0.0003
945 PNEUMONIA ASPIRATION 7 0.0003
946 CONVULSION 16 0.0003
947 CEREBRAL HAEMORRHAGE 10 0.0003
948 NO ADVERSE EVENT 50 0.0003
949 ANGIOEDEMA 12 0.0003
950 LABORATORY TEST ABNORMAL 8 0.0003
951 MUCOSAL INFLAMMATION 7 0.0003
952 BRADYCARDIA 14 0.0003
953 HAEMATURIA 9 0.0003
954 JAUNDICE 7 0.0003
955 DEVICE MALFUNCTION 18 0.0003
956 CARDIAC ARREST 21 0.0003
957 MEDICATION ERROR 14 0.0003
958 DRUG DOSE OMISSION 41 0.0002
959 ACCIDENTAL OVERDOSE 9 0.0002
960 INTERNATIONAL NORMALISED RATIO INCREASED 7 0.0002
961 EXPOSURE DURING PREGNANCY 15 0.0002
962 PSYCHOTIC DISORDER 7 0.0002
963 PREMATURE BABY 7 0.0002
964 DEVICE DISLOCATION 10 0.0002
965 EPILEPSY 7 0.0002
966 OVERDOSE 49 0.0002
967 SEIZURE 26 0.0002
968 INCORRECT ROUTE OF DRUG ADMINISTRATION 8 0.0002
969 BONE DENSITY DECREASED 7 0.0002
970 DEVICE BREAKAGE 9 0.0002
971 MALIGNANT NEOPLASM PROGRESSION 22 0.0002
972 BLOOD CREATININE INCREASED 13 0.0002
973 BREAST CANCER 18 0.0002
974 CARDIO-RESPIRATORY ARREST 8 0.0002
975 DRUG WITHDRAWAL SYNDROME 16 0.0002
976 DRUG DOSE OMISSION BY DEVICE 14 0.0002
977 RHABDOMYOLYSIS 7 0.0002
978 PROSTATE CANCER 13 0.0002
979 MULTIPLE SCLEROSIS RELAPSE 11 0.0002
980 UNDERDOSE 11 0.0002
981 DEATH 123 0.0001
982 TOXICITY TO VARIOUS AGENTS 23 0.0001
983 AGITATION 10 0.0001
984 DEVICE DIFFICULT TO USE 8 0.0001
985 AGGRESSION 6 0.0001
986 DRUG ABUSE 9 0.0001
987 DRUG DEPENDENCE 7 0.0000